share_log

MAIA Biotechnology, Inc. Stock Up 8.78% Since IPO

MAIA Biotechnology, Inc. Stock Up 8.78% Since IPO

Maia Biotech,Inc.股票自首次公开募股以来上涨8.78%
Benzinga Real-time News ·  2022/07/30 06:10

$MAIA Biotechnology(MAIA.US)$ opened up its shares for public trading for the first time since it filed for IPO in April 2022. The company agreed to initially offer 2.00 million shares to the public at a $5.00 per share. On its first day of trading, the stock increased 8.78% from its opening price of $4.1 to its closing price of $4.46.

$Maia Biotech(MAIA.US)$ 自2022年4月申请IPO以来,该公司首次开放股票公开交易。该公司同意最初以每股5澳元的价格向公众发行200万股。在第一个交易日,该股从4.1美元的开盘价上涨了8.78%,收盘价为4.46美元。

MAIA Biotechnology, Inc. Performance On First Day of Trading

Maia Biotech,Inc.上市首日表现

About MAIA Biotechnology, Inc. and It's IPO

关于Maia Biotech公司及其首次公开募股

MAIA Biotechnology, Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO, our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity.

Maia Biotech,Inc.是一家临床阶段的生物制药公司,为癌症开发靶向免疫疗法。THIO是我们的主要资产,是一种研究中的双重作用机制,候选药物结合了端粒靶向和免疫原性。

For its IPO, MAIA agreed to offer 2.00 million shares at a price of $5.00 per share, with an insider lock-up period of 180 days, ending on January 24, 2023.

对于首次公开募股,Maia同意以每股5.00美元的价格发行200万股,内部禁售期为180天,至2023年1月24日结束。

An insider lock-up period is a period of time after a company first goes public where major shareholders are not allowed to sell their shares. The insider lock-up period makes sure that the market does not get oversupplied with shares of the company.

内部人禁售期是一家公司首次上市后的一段时间,在这段时间里,大股东不允许出售他们的股票。内部人禁售期确保了市场不会出现公司股票供应过剩的情况。

Traders may short the stock leading up to the lockup-period expiration date in hopes that the price will fall due to an increase in supply of shares. Retail traders should be watching this stock's short interest as it moves closer to lockup expiration.

交易员可能会在禁售期到期前做空股票,希望股票价格会因股票供应增加而下跌。散户交易员应该关注这只股票的空头股数,因为它接近锁定到期。


This article was generated by Benzinga's automated content engine and reviewed by an editor.

本文由Benzinga的自动内容引擎生成,并由编辑审阅。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发